Clinical Trials Browser

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT01696461 2023-09-14

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03244930 2017-08-10

Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation

Phase 2 Unknown

20 enrolled

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT01158118 2017-06-05

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Phase 2 Completed

48 enrolled 17 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02200380 2017-04-07

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

Phase 2 Terminated

36 enrolled

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01164345 2015-12-03

Mozobil for Autologous Stem Cell Mobilization

Phase 2 Completed

20 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT00901225 2014-05-07

Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant

Phase 2 Completed

21 enrolled 8 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT00396201 2014-03-13

AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease

Phase 2 Completed

22 enrolled 17 charts

Lymphoid

Hodgkin Disease

NCT00665314 2014-02-11

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

Phase 2 Completed

5 enrolled

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

Clinical Trials

HSCT

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

Mozobil for Autologous Stem Cell Mobilization

Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant

AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).